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A B S T R A C T
The Kidney Disease: Improving Global Outcomes (KDIGO) work group released recommendations in 2006
to deﬁne the bone-related pathology associated with chronic kidney disease as renal osteodystrophy. In
2009, KDIGO released revised clinical practice guidelines which redeﬁned systemic disorders of bone
and mineral metabolism due to chronic kidney disease as chronic kidney disease-mineral and bone dis-
orders. Conditions under this overarching term include osteitis ﬁbrosa cystica, osteomalacia, and adynamic
bone disease. We aim to provide a brief review of the histopathology, pathophysiology, epidemiology,
and diagnostic features of adynamic bone disease, focusing on current trends in the management of this
complex bone disorder.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Patients with end-stage renal disease (ESRD) requiring hemo-
dialysis have an increased fracture risk, where the incidence of hip
fractures in one study was fourfold greater in ESRD patients on di-
alysis when compared to non-dialysis patients [1]. Chronic kidney
disease (CKD) is associated with various bone-related patholo-
gies, each with unique histopathological ﬁndings. In spite of their
varied underlying processes, the clinical presentations of the dis-
eases which comprise chronic kidney disease-mineral and bone
disorders (CKD-MBD) are oftentimes similar [2]. Patients with ady-
namic bone disease (ABD), a condition of low-bone turnover, and
those with osteitis ﬁbrosa cystica (OFC), a condition of high-bone
turnover, are typically asymptomatic at the time of their diagno-
sis, though either can present with fragility fractures.
Histopathology
ABD is characterized by markedly low-bone turnover resulting
from a reduced number of osteoclasts and osteoblasts without
osteoid accumulation [3]. This distinguishes ABD from OFC, which
in contrast, is a disorder characterized by increased bone turnover
with a resulting increase in bone formation and resorption [4] [Fig. 1].
Pathophysiology
The underlying pathophysiology of ABD is both intricate and
multi-factorial. Fundamentally, ABD is due to either the resistance
of parathyroid hormone (PTH) on bone metabolism or the
oversuppression of PTH release, though several events precede this
outcome. One of the earliest biomarkers of CKD appears to be a de-
creased expression in α-Klotho, which is a co-receptor of the
phosphatonin Fibroblast growth factor 23 (FGF-23) [5]. This peptide
is secreted by osteocytes and osteoblasts in response to elevated
phosphate and calcitriol levels thus allowing for increased excre-
tion of phosphate [6]. The resistance to FGF-23 by the decreased
expression of α-Klotho leads to an increase in FGF-23 production,
a decrease in calcitriol, relative hypocalcemia, and secondary hy-
perparathyroidism [5,7]. This cascade eventually results in PTH
receptor down-regulationwith subsequent skeletal resistance to PTH
action [8].
Oversuppression of PTH is an additional hallmark of ABD.
While very high levels of PTH are associated with an increase in both
fracture risk and mortality, normalizing the secondary hyperpara-
thyroidism associated with early and late-stage CKD can also lead
to similar increases in morbidity [9]. Patients with CKD and intact
parathyroid hormone (iPTH) levels <195 pg/mL have been found to
have a 22% increased risk of fractures as studied retrospectively by
Atsumi et al. [10]. Hence, dietary phosphate restriction, the use of
calcium-based phosphate binders, activated vitamin D analogs, and
calcimimetics can all trigger PTH suppression thus creating a low-
bone-turnover state [8,11].
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Epidemiology
Of the disorders which comprise CKD-MBD, ABD is by far the
most prevalent and should therefore be at the forefront of meta-
bolic bone disease management. In patients with CKD stages 3–5,
there is an 18% prevalence of ABD [2]. This low-bone-turnover
disease is seen in 50% of patients with CKD-MBD who receive peri-
toneal dialysis and in 19% of CKD-MBD patients receiving
hemodialysis [2,8,12]. Several direct and indirect risk factors for
ABD exist and include the use of calcium-based phosphate binders,
activated vitamin D analogs, calcimimetics, peritoneal dialysis,
high-calcium dialysate, glucocorticoid-induced osteoporosis,
bisphosphonate use, diabetes, post-menopausal state, hypogonad-
ism, increased age, malnutrition, parathyroidectomy, and systemic
inﬂammation [2–8,12]. Of the aforementioned risk factors, the in-
creased global prevalence of diabetes and ESRD, as well as the
aggressive treatment of secondary hyperparathyroidism have greatly
contributed to the growing prevalence of ABD over the past 20
years [3].
Diagnosis
Bone biopsy remains the diagnostic gold standard in distin-
guishing a disease of low-bone turnover such as ABD from other
bone-related pathologies such as OFC which is characterized by a
marked increase in bone turnover and remodeling [4]. Guidelines
set forth by the KDIGO work group as well as the National Kidney
Foundation: Kidney Disease Outcomes Quality Initiative (NKF KDOQI)
recommend performing a bone biopsy in patients with CKD who
also possess one or more of the following conditions [2,3,13]:
• Patients with iPTH levels between 100 and 500 pg/mL with un-
explained hypercalcemia, bone pain, or increased bone-speciﬁc
alkaline phosphatase (BSAP)
• Fragility fractures not explained by additional etiologies such as
malignancy
• Prior to initiating bisphosphonate therapy
• Unexplained hypercalcemia
• Suspected aluminum toxicity
• Severe vascular calciﬁcation
Serological markers, though unable to solely conﬁrm the diag-
nosis of ABD, can be helpful in guiding clinicians who are unsure
of whether or not to proceed with a bone biopsy. This especially
holds true in the case of an asymptomatic patient, as persistent bone
pain and fragility fractures are seen in only a minority of patients
at the time of their initial diagnosis [8]. Patients with PTH levels
<150 pg/mL have a 97% positive predictive value for ABD, whereas
PTH levels >450 pg/mL have a 100% positive predictive value for OF
[14]. One serum marker directly implicated in assessing bone for-
mation is BSAP [8]. BSAP of >20 ng/mL virtually excludes the
diagnosis of ABD particularly when patients have a concurrent PTH
>200 pg/mL. Patients with BSAP <12.9 ng/mL can further bolster the
diagnosis of ABD as this is 100% sensitive and 93.7% speciﬁc [8,15,16].
Management
In spite of its underlying complexity, the traditional therapies
geared toward managing ABD are ﬁrmly rooted in the prevention
of CKD progression, management of ABD risk factors such as dia-
betes, and decreasing calcium and vitamin D load so as to relax PTH
suppression in order to re-establish its activity [3,8].
Relaxing PTH suppression
As discussed earlier, several factors are involved in the suppres-
sion of PTH which can ultimately lead to ABD in patients with CKD.
Though the most favorable PTH level to maintain in patients with
CKD stages 3–5 is currently not known, the 2009 KDIGO Guide-
lines suggest maintaining iPTH levels for patients with CKD stage
5D between 2 and 9 times the upper limit of normal for the assay
utilized [2].
The administration of activated vitamin D analogs can cause de-
creased bone turnover in patients with CKD. In a 1994 study by
Goodman et al., 6 out of 14 study participants with end-stage renal
disease developed biopsy-proven ABD following the administra-
tion of high dose calcitriol [17]. Therefore, limiting the use of calcitriol
can assist in alleviating PTH oversuppression which is a driving force
for the development of ABD. Similarly, the use of calcimimetics
should be avoided in patients who have developed this low-bone-
turnover disease seeing that thesemedications also serve to suppress
PTH activity [8]. Consideration should also be given toward switch-
ing patients with ESRD receiving hemodialysis from a calcium-
containing phosphate binder to a non-calcium-containing phosphate
binder, as this could assist in relaxing PTH suppression and
Figure 1. a: Adynamic bone disease. Depicts a classic bone biopsy featuring minimal
osteoid (black arrow) and nearly no activity of osteoblasts or osteoclasts. Image cour-
tesy of Avudai Maran, PhD and Bart Clarke, MD – Biomaterials and Histomorphometry
Core Lab, Mayo Clinic, Rochester, MN. b: Osteitis ﬁbrosa cystica. Characterized by
thick osteoid production (white arrow) with increased osteoclast activity (yellow
arrow). Image courtesy of Avudai Maran, PhD and Bart Clarke, MD – Biomaterials
and Histomorphometry Core Lab, Mayo Clinic, Rochester, MN. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to theWeb version
of this article.)
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increase the rate of bone formation. In a study of 68 patients with
ESRD on hemodialysis, Ferreira et al. showed that patients receiv-
ing sevelamer experienced an increase in bone formation rate per
bone surface from their baseline when compared to patients re-
ceiving calcium carbonate [18]. Also pertinent for patients
undergoing dialysis is the use of low-calcium dialysate. A 2006 pro-
spective study by Haris et al. revealed that the use of a low-
calcium dialysate in 51 patients with biopsy-proven ABD receiving
peritoneal dialysis not only lowered levels of serum ionized calcium,
but led to an increase in PTH and a signiﬁcant improvement in bone
turnover [19].
Treatment with teriparatide
Teriparatide (PTH 1–34), which has been FDA approved to treat
post-menopausal osteoporosis, may have a growing role in the treat-
ment of ABD. Seeing that ABD is a disease process caused by both
PTH resistance and relative PTH deﬁciency, it would seem that the
use of this PTH analog could be beneﬁcial in improving bone-
related outcomes.
An English-language literature search for teriparatide and ABD
revealed 4 individual studies where a total of 17 patients with biopsy-
proven ABD received teriparatide therapy [20–23]. The results from
these studies are promising in that patients receiving teriparatide
not only sustained increases to their PTH levels, but saw improve-
ment in their bone mineral density (BMD) as measured on Dual-
energy X-ray Absorptiometry (DXA) in all 4 studies [20–23]. Though
these studies speculate that increased BMDmay also result in a de-
creased fracture risk, no supportive data are currently available.
Pipeline anabolic therapies
The future of ABD treatment is a promising area for research,
as several anabolic therapies currently in development for the treat-
ment of post-menopausal osteoporosis could also potentially offer
novel therapies for ABD.
Abaloparatide
Parathyroid hormone-related peptide (PTHrP) activates the PTH
type 1 receptor, which when done intermittently, can lead to bone
formation and increased osteoblast activity. Abaloparatide is a frag-
ment of PTHrP (1–34) which has been shown to exert these
aforementioned effects in both Phase II and Phase III trials in post-
menopausal women with osteoporosis [24]. In a 2015 multi-
center, multi-national, double-blind, placebo-controlled trial by Leder
et al., post-menopausal women with osteoporosis who received
80 mcg of abaloparatide daily for 24 weeks experienced a 6.7% in-
crease in the BMD of their lumbar spine and a 2.6% increase in the
BMD of their total hip [25]. Furthermore, their risk of sustaining a
major osteoporotic fracture was reduced by 67% when compared
to teriparatide [26]. Given these ﬁndings, one could speculate that
patients with ABD could sustain similar increases in bone forma-
tion with improvements to their BMD, as well as a reduction to their
fracture risk with abaloparatide use.
Romosozumab
Thewingless in Drosophila and integrated in vertebrate (Wnt) sig-
naling pathway is a crucial regulator of osteoblast recruitment.
Sclerostin is an endogenous inhibitor of this pathway, thereby in-
hibiting osteoblast recruitment and decreasing bone formation [27].
The use of romosozumab, a sclerostin antibodywhich possesses ana-
bolic properties, is currently in Phase III trials for the treatment of
post-menopausal osteoporosis. Based on pooled clinical trial data,
the use of a monthly, 210-mg, subcutaneous dose of romosozumab
resulted in an 11.3% increase in the BMD of the lumbar spine and
a 4.1% increase in the BMD of the total hip [24]. Based on themarked
improvements noted in BMD for the treatment of post-menopausal
osteoporosis, similar success in using romosozumab to improve bone
density in patients with ABD may be promising.
Ronacaleret
Endogenous PTH release can be stimulated when calcium-
sensing receptor (CASR) activity is inhibited. Ronacaleret is a calcilytic
which allows for bone formation by serving as a CASR antagonist,
thus increasing endogenous production of PTH [28]. In a 2012 ran-
domized, placebo-controlled, dose-ranging trial by Fitzpatrick et al.,
the effects of ronacaleret on volumetric BMD (vBMD) as measured
by quantitative computed tomography, was studied in women with
post-menopausal osteoporosis, as compared to both teriparatide and
alendronate [28]. Patients treated with teriparatide saw an im-
provement in vBMD of both the lumbar and trabecular spine, with
increases of 14.8% and 24.4%, respectively. Ronacaleret, adminis-
tered at a 400-mg daily dose for 12 months, was associated with a
3.9% increase in vBMD in the lumbar spine and a 13.3% increase in
the trabecular spine, though, a 1.79% decrease in the cortical femur
vBMD was observed at this dose. This, however, was not seen with
teriparatide. The decrease at cortical sites could be attributed to the
duration of the increase in PTH production. This could prove to be
a limiting factor in the development of these agents. Regardless, it
is interesting to consider the potential beneﬁts of such a therapy
on ABD.
Conclusion
ABD is a complex disease process which, given its increasing prev-
alence and associated morbidity, requires careful diagnosis and
management. This disorder is characterized by histopathological ﬁnd-
ings of low bone turnover and pathophysiological features of both
PTH resistance and oversuppression. The management of underly-
ing ABD risk factors is paramount, particularly with the increased
incidence of diabetes, ESRD, and aggressive treatment of second-
ary hyperparathyroidism. In addition to controlling risk factors and
balancing the risks and beneﬁts of PTH suppression, the use of novel
anabolic bone therapies could provide clinicians with new thera-
peutic options to potentially improve bone-related outcomes in
patients with this unique disease process.
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